All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
Sleeping Beauty (SB) transposon, a type of nonviral integrative vectors, provides an alternative to modify primary T cells. Creative biolabs has developed SB transposon CAR vector pSBCAR1 CD20 (Leu16) h(28BBζ), which is constructed for the engineering of T cells to target human CD20. The T cells are genetically modified through transduction with a nonviral vector expressing scFv of anti-CD20 antibody linked to a CD28 transmembrane domain/ endodomain and CD137 (4-1BB), CD3-zeta signaling domains. And the vector product was designed for the treatment of Acute lymphoblastic leukemia (ALL).
CAR Construction : leu-16-CD28-41BB-CD3ζ Fig.1 Specific cytotoxicity assay. CD20-specific cytotoxicity of G418-selected autologous patient T cells was assessed with 5-hour chromium-release assays using the following 51Cr-labeled target cells: Granta cells (MCL), Daudi cells (Burkitt NHL), EL4 cells transfected to express CD20, or the parental EL4 cell line lacking CD20 expression. Till, B. G., Jensen, M. C., Wang, J., Qian, X., Gopal, A. K., Maloney, D. G., ... & Press, O. W. (2012). CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. Blood, The Journal of the American Society of Hematology, 119(17), 3940-3950. |
CAR Construction : leu-16-CD28-41BB-CD3ζ Fig.2 Change in tumor volume over time. The sum of the products of the diameters of the 7 largest lymph nodes seen on the baseline and 1-, 6-, and 12-month CT scans. Till, B. G., Jensen, M. C., Wang, J., Qian, X., Gopal, A. K., Maloney, D. G., ... & Press, O. W. (2012). CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. Blood, The Journal of the American Society of Hematology, 119(17), 3940-3950. |
CAR Construction : leu-16-CD28-41BB-CD3ζ Fig.3 Immune responses against modified cells. An ELISA testing Ab binding to the murine Leu16 from which the αCD20-28-BB-ζ scFv is derived (Figure A); and a flow cytometry-based assay using HEK-293 cells transfected with the L29.19.1 plasmid (Figure B). No convincing evidence indicated humoral immune responses to the infused cells. Cellular immune responses were tested (Figure C). No evidence indicated cellular immune responses against the modified T cells Till, B. G., Jensen, M. C., Wang, J., Qian, X., Gopal, A. K., Maloney, D. G., ... & Press, O. W. (2012). CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. Blood, The Journal of the American Society of Hematology, 119(17), 3940-3950. |
CAR Construction : leu-16-CD28-41BB-CD3ζ Fig.4 Anti-tumor effect of transduced T cells in vivo. NSG mice were inoculated i.v. with Raji-ffLuc tumors followed 2 days later by infusion of 5 × 106^6 CD20-targeted CAR+T cells, with or without i.p. injection of 30 mg i.v immune globulin (IVIG) per mouse 4 hours prior to T cell infusion. Survival curves is compared using a log-rank (Mantel-Cox) test. Lee, S. Y., Olsen, P., Lee, D. H., Kenoyer, A. L., Budde, L. E., O’Steen, S., ... & Till, B. G. (2018). Preclinical optimization of a CD20-specific chimeric antigen receptor vector and culture conditions. Journal of immunotherapy (Hagerstown, Md.: 1997), 41(1), 19. |
CAR Construction : leu-16-CD28-CD3ζ Fig.5 Anti-tumor effect of transduced T cells in vivo. NSG mice were injected intravenously (i.v.) with 0.5 × 10^6 firefly-luciferase-expressing Raji cells 6 days prior to treatment with 5 × 10^6 CD8+ CD20-targeting CAR-T cells delivered i.v. Tumor progression was monitored by bioluminescence imaging. Black dotted line in the right data box denotes day 12 post T-cell injection, the time at which the CAR-T cell group began to rapidly lose tumor control. Chen, X., Khericha, M., Lakhani, A., Meng, X., Salvestrini, E., Chen, L. C., ... & Chen, Y. Y. (2020). Rational tuning of CAR tonic signaling yields superior T-cell therapy for cancer. bioRxiv. |
CAR Construction : leu-16-CD28-CD3ζ Fig.6 Evualution of tumor activation and exhaustion. Activation and exhaustion maker expression on CAR+ T cells were evaluated 11 days post Dynabead removal, without CD20 antigen stimulation. Chen, X., Khericha, M., Lakhani, A., Meng, X., Salvestrini, E., Chen, L. C., ... & Chen, Y. Y. (2020). Rational tuning of CAR tonic signaling yields superior T-cell therapy for cancer. bioRxiv. |
CAR Construction : Fig.7 Competition cell-binding assay. Binding to CD20-positive Daudi cells was evaluated by competition of parental Leu-16 or scFv-Fc with FITC-Leu-16 by FACS. (A) GS18/C233S scFv-Fc. (B) GS8/nat scFv-Fc. Wu A M, Tan G J, Sherman M A, et al. Multimerization of a chimeric anti-CD20 single-chain Fv-Fc fusion protein is mediated through variable domain exchange[J]. Protein engineering, 2001, 14(12): 1025-1033. |
More Published Data More Published Data
There are currently no customer reviews or questions for Anti-CD20 (Leu16) h(CD28-41BB-CD3ζ) CAR, pSBCAR1 (CAR-SB-02LX005). Click the button below to contact us or submit your feedback about this product.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION